The Capsule of Cryptococcus neoformans Reduces T-Lymphocyte Proliferation by Reducing Phagocytosis, Which Can Be Restored with Anticapsular Antibody
暂无分享,去创建一个
C. Mody | T. Kozel | R. Syme | T. F. Bruno
[1] A. Casadevall,et al. Specific Antibody to Cryptococcus neoformans Alters Human Leukocyte Cytokine Synthesis and Promotes T-Cell Proliferation , 1998, Infection and Immunity.
[2] F. Bistoni,et al. Encapsulation of Cryptococcus neoformans with Glucuronoxylomannan Inhibits the Antigen-Presenting Capacity of Monocytes , 1998, Infection and Immunity.
[3] F. Bistoni,et al. Regulatory role of exogenous IL‐10 in the development of immune response versus Cryptococcus neoformans , 1997, Clinical and experimental immunology.
[4] A. Casadevall,et al. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[5] A. Casadevall,et al. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. , 1997, Journal of immunology.
[6] M. Burdick,et al. Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. , 1996, Journal of immunology.
[7] L. Pirofski,et al. Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies , 1996, Infection and immunity.
[8] F. Bistoni,et al. Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes , 1996, Infection and immunity.
[9] S. Devi. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. , 1996, Vaccine.
[10] J. Murphy,et al. Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils. , 1996, The Journal of clinical investigation.
[11] J. Verhoef,et al. Quantitative analysis of phagocytosis and killing of Cryptococcus neoformans by human peripheral blood mononuclear cells by flow cytometry , 1995, Clinical and diagnostic laboratory immunology.
[12] T. Beccari,et al. Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes , 1995, Infection and immunity.
[13] L. Pirofski,et al. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine , 1995, Infection and immunity.
[14] E. A. Havell,et al. Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice , 1995, Infection and immunity.
[15] M. Puliti,et al. Biomolecular events involved in anticryptococcal resistance in the brain , 1995, Infection and Immunity.
[16] L. Pirofski,et al. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV− individuals , 1995, Clinical and experimental immunology.
[17] A. Casadevall,et al. Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. , 1995, Journal of immunology.
[18] A. Casadevall,et al. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages , 1995, Infection and immunity.
[19] A. Casadevall,et al. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell , 1995, The Journal of experimental medicine.
[20] F. Bistoni,et al. Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages , 1994, Clinical and experimental immunology.
[21] T. Kozel,et al. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan , 1994, Infection and immunity.
[22] A. Casadevall,et al. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B , 1994, Antimicrobial Agents and Chemotherapy.
[23] T. Kozel,et al. Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans , 1993, Infection and immunity.
[24] C. Mody,et al. Effect of polysaccharide capsule and methods of preparation on human lymphocyte proliferation in response to Cryptococcus neoformans , 1993, Infection and immunity.
[25] M. de Carli,et al. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. , 1993, Journal of immunology.
[26] R. Coker. Cryptococcal Infection in AIDS , 1992, International journal of STD & AIDS.
[27] G. Bancroft,et al. Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses , 1991, Infection and immunity.
[28] C G Figdor,et al. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes , 1991, The Journal of experimental medicine.
[29] Devi,et al. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity , 1991, Infection and immunity.
[30] R. Maziarz,et al. Killing of Cryptococcus neoformans by human peripheral blood mononuclear cells stimulated in culture. , 1991, The Journal of infectious diseases.
[31] S. Levitz,et al. Binding of Cryptococcus neoformans by human cultured macrophages. Requirements for multiple complement receptors and actin. , 1991, The Journal of clinical investigation.
[32] S. Levitz,et al. Growth inhibition of Cryptococcus neoformans by cultured human monocytes: role of the capsule, opsonins, the culture surface, and cytokines , 1990, Infection and immunity.
[33] F. Dromer,et al. Role of IgG and complement component C5 in the initial course of experimental cryptococcosis. , 1989, Clinical and experimental immunology.
[34] T. Kozel,et al. Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific for the capsular polysaccharide , 1989, Infection and immunity.
[35] T. Kozel,et al. Strain variation in phagocytosis of Cryptococcus neoformans: dissociation of susceptibility to phagocytosis from activation and binding of opsonic fragments of C3 , 1988, Infection and immunity.
[36] S. Levitz,et al. Differential stimulation of murine resident peritoneal cells by selectively opsonized encapsulated and acapsular Cryptococcus neoformans , 1988, Infection and immunity.
[37] I. Grant,et al. Fungal infections in AIDS. Cryptococcosis. , 1988, Infectious disease clinics of North America.
[38] W. Dismukes. Cryptococcal meningitis in patients with AIDS. , 1988, The Journal of infectious diseases.
[39] C. Mody,et al. Cyclosporin A inhibits the growth of Cryptococcus neoformans in a murine model , 1988, Infection and immunity.
[40] T. Kozel,et al. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide , 1987, Infection and immunity.
[41] T. G. Mitchell,et al. Strain variation in composition and molecular size of the capsular polysaccharide of Cryptococcus neoformans serotype A , 1986, Infection and immunity.
[42] T. Kozel,et al. Binding of cryptococcal polysaccharide to Cryptococcus neoformans , 1984, Infection and immunity.
[43] J. Repine,et al. Opsonic requirements for the uptake of Cryptococcus neoformans by human polymorphonuclear leukocytes and monocytes. , 1982, The Journal of infectious diseases.
[44] E. Jacobson,et al. Genetic and phenotypic characterization of capsule mutants of Cryptococcus neoformans , 1982, Journal of bacteriology.
[45] T. Kozel,et al. Opsonization of Cryptococcus neoformans by human immunoglobulin G: role of immunoglobulin G in phagocytosis by macrophages , 1979, Infection and immunity.
[46] T. Kozel. Non-encapsulated variant of Cryptococcus neoformans. II. Surface receptors for cryptococcal polysaccharide and their role in inhibition of phagocytosis by polysaccharide , 1977, Infection and immunity.
[47] T. Kozel,et al. Inhibition of phagocytosis by cryptococcal polysaccharide: dissociation of the attachment and ingestion phases of phagocytosis , 1976, Infection and immunity.
[48] T. G. Mitchell,et al. In Vitro Phagocytosis and Intracellular Fate of Variously Encapsulated Strains of Cryptococcus neoformans , 1972, Infection and immunity.
[49] T. Kozel,et al. Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide , 1971, Infection and immunity.
[50] J. Bennett,et al. Serologic Grouping of Cryptococcus neoformans , 1968, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.